According to research findings published by Anthropic on October 20, 2026, an internal artificial intelligence model operating within Claude Science has designed de novo protein minibinders capable of binding human-lethal scorpion venom neurotoxins. The project, conducted in collaboration with financial research firm Citrini Research and experimentally evaluated by contract research organizations Adaptyv Bio and Twist Bioscience, successfully produced 17 laboratory-confirmed binding proteins from an initial generative campaign.
Scorpion envenomation represents an acute neglected global health crisis. Every year, scorpions sting an estimated 1.2 million people worldwide, causing over 3,250 fatalities, disproportionately impacting children in rural, low-resource tropical regions where access to healthcare is limited. Current therapeutic antivenoms rely on century-old methods: harvesting polyclonal antibodies from the blood plasma of immunized horses or sheep. These animal-derived formulations are expensive to produce, carry high risks of severe anaphylactic shock or serum sickness, and require fragile refrigerated cold chains that are frequently absent in rural clinics.
To explore whether autonomous AI systems could compress the front end of neglected disease therapeutics, the researchers challenged Claude to engineer minibinders—compact, computationally designed proteins that attach with high affinity to target molecules. Initiating the workflow from an initial prompt and steering execution through just four subsequent follow-ups over a 64-hour span, Claude operated largely autonomously. The system analyzed structural data for five high-potency neurotoxins across four medically significant scorpion species, which act by binding voltage-gated sodium channels in human nerve membranes to trigger massive autonomic nervous discharge and fatal pulmonary edema.
Across the campaign, Claude generated 318,484 candidate protein designs, ranking and filtering them down to 180 prioritized constructs. The research team added 31 additional variants based on Claude's intermediate recommendations, resulting in 211 unique sequences. Adaptyv Bio and Twist Bioscience then physically synthesized the DNA, expressed the proteins, and tested their real-world binding affinities using high-throughput biophysical assays. Out of the 211 physical candidates, 17 met the stringent empirical criteria for high-affinity target binding.
External peer evaluators, including structural biologists Susana Vázquez Torres from the Spanish National Cancer Research Centre (CNIO) and Timothy P. Jenkins, praised the turnaround speed while cautioning on subsequent translation. Anthropic explicitly noted that while the minibinders achieved verified target binding in vitro, the team has not yet established whether they effectively neutralize neurotoxin activity in living tissue models. To advance open science, Anthropic has released the full sequences, structural models, and biophysical binding telemetry for all 211 tested designs into the public domain.